JohannesCzerninMD

Nuclear Medicine • Los Angeles, CA

Professor, Molecular & Medical Pharmacology, UCLA School of Medicine Chief of the Ahmanson Translational Imaging Division at UCLA

Join to view full profile

Dr. Czernin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Czernin's full profile

Already have an account?

Office
10833 Le Conte Ave
Los Angeles, CA 90095
Phone+1 310-301-6800

Fax+1 310-267-0227

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Nuclear Medicine, 1994 - 1995
University of Vienna Faculty of MedicineClass of 1983

Certifications & Licensure

CA State Medical License 1996 - 2026
American Board of Nuclear Medicine Nuclear Medicine

Awards, Honors, & Recognition

Los Angeles Magazine Top Doctors 2018

Clinical Trials

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma Start of enrollment: 2006 Jan 01
Completed
Not Applicable
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants Start of enrollment: 2004 May 04
Terminated
Not Applicable
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy Start of enrollment: 2004 Dec 01
Completed
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Start of enrollment: 2009 Jan 01
Unknown status
Phase 3
Roles: Principal Investigator, Contact
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma Start of enrollment: 2012 Aug 22
Completed
Not Applicable
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Start of enrollment: 2018 Apr 02
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually).
Johannes Czernin, Lisa Bodei, Irvin Modlin, Jeremie Calais
Journal of Nuclear Medicine. 2025-02-06
From Scientist to Analyst to Strategist: Aharon (Ronny) Gal Talks with Ken Herrmann and Johannes Czernin About Leadership in Multinational Pharma.
Aharon Ronny Gal, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine. 2025-02-03
Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development.
Jacob S Van Naarden, Ken Herrmann, Johannes Czernin
Journal of Nuclear Medicine. 2025-01-23

Press Mentions

Legacy of Theranostics Innovation Transforms Cancer CareJanuary 15th, 2025
JNM Maintains Strong Metrics in 2023 Journal Citation ReportsJuly 24th, 2024
UCLA Researchers Receive Grant from Prostate Cancer FoundationDecember 14th, 2022
Join now to see all

Other Languages

German